Literature DB >> 30848400

Disease activity is associated with cognitive impairment in patients with rheumatoid arthritis.

Wanruchada Katchamart1, Pongthorn Narongroeknawin2, Nattharadee Phutthinart3, Varalak Srinonprasert4, Weerasak Muangpaisan5, Sumapa Chaiamnauy2.   

Abstract

OBJECTIVE: To investigate the association between disease activity and cognitive impairment in patients with rheumatoid arthritis (RA).
METHODS: A total of 464 patients from the rheumatoid arthritis registry of two academic centers, Siriraj and Phramongkutklao hospitals, were included. Demographic, clinical, and laboratory data related to disease activity and functional status were collected. Cognitive function was assessed using the Thai version of the Montreal Cognitive Assessment (MoCA-T). Subjects were classified as cognitively impaired if they scored less than 25.
RESULTS: Most subjects (85%) were female with a mean age ± SD of 59.2 ± 11.4 years old and a median (range) educational level of 9 (4-14) years. They were long-standing RA patients (median disease duration (range) of 9.9 (5.1-16.6) years) and had moderate cumulative disease activity (mean DAS28 ± SD of 3.5 ± 0.81) and mild functional impairment (median HAQ (range) 0.5 (0.13-1.10)). Seventy percent of the patients were classified as having cognitive impairment. The patients with cognitive impairment significantly impaired in all domains, especially in visuospatial/executive, language, and abstraction. In multiple logistic regression analyses, old age (RR 3.45, 95% CI 2-6, p < 0.001), low education (RR 10.8, 95% CI 5.3-22.1, p < 0.001), and high cumulative disease activity (RR 2.2, 95% CI 1.07-4.7, p = 0.033) were independently associated with cognitive impairment.
CONCLUSION: High cumulative RA disease activity is associated with cognitive impairment. Therefore, treat-to-target aimed at low disease activity or remission may be beneficial for preventing cognitive decline in RA patients.

Entities:  

Keywords:  Cognitive impairment; DAS28; Disease activity; HAQ; MoCA; Rheumatoid arthritis

Mesh:

Year:  2019        PMID: 30848400     DOI: 10.1007/s10067-019-04488-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  7 in total

1.  Rheumatoid Arthritis, Cognitive Impairment, and Neuroimaging Biomarkers: Results from the Mayo Clinic Study of Aging.

Authors:  Maria Vassilaki; Cynthia S Crowson; John M Davis Iii; Stephanie Q Duong; David T Jones; Aivi Nguyen; Michelle M Mielke; Prashanthi Vemuri; Elena Myasoedova
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

Review 2.  Inflammaging and Frailty in Immune-Mediated Rheumatic Diseases: How to Address and Score the Issue.

Authors:  Fausto Salaffi; Andrea Di Matteo; Sonia Farah; Marco Di Carlo
Journal:  Clin Rev Allergy Immunol       Date:  2022-05-21       Impact factor: 10.817

3.  A Computerized Assessment of Verbal and Visuospatial Memory (Dys)functions in Patients with Rheumatoid Arthritis.

Authors:  Cristian Vasile Petra; Laura Visu-Petra; Monica Buta; Maria Magdalena Tămaș; Oana Benga; Simona Rednic
Journal:  Psychol Res Behav Manag       Date:  2020-08-04

4.  Fatigue in inflammatory rheumatic disorders: pathophysiological mechanisms.

Authors:  S Mechiel Korte; Rainer H Straub
Journal:  Rheumatology (Oxford)       Date:  2019-11-01       Impact factor: 7.580

Review 5.  Cognitive Decline in Rheumatoid Arthritis: Insight into the Molecular Pathogenetic Mechanisms.

Authors:  Maria Sofia Basile; Rosella Ciurleo; Alessia Bramanti; Maria Cristina Petralia; Paolo Fagone; Ferdinando Nicoletti; Eugenio Cavalli
Journal:  Int J Mol Sci       Date:  2021-01-26       Impact factor: 5.923

6.  Longitudinal Study of Cognitive Functioning in Adults with Juvenile Idiopathic Arthritis.

Authors:  Natalia Mena-Vázquez; Fernando Ortiz-Márquez; Pablo Cabezudo-García; Claudia Padilla-Leiva; Gisela Diaz-Cordovés Rego; Luis Muñoz-Becerra; Teresa Ramírez-García; Jose Manuel Lisbona-Montañez; Sara Manrique-Arija; Arkaitz Mucientes; Esmeralda Núñez-Cuadros; Rocío Galindo Zavala; Pedro Jesús Serrano-Castro; Antonio Fernández-Nebro
Journal:  Biomedicines       Date:  2022-07-18

7.  Inhibiting peripheral and central MAO-B ameliorates joint inflammation and cognitive impairment in rheumatoid arthritis.

Authors:  Woojin Won; Hyun-Ji Choi; Ji-Young Yoo; Daeun Kim; Tai Young Kim; YeonHa Ju; Ki Duk Park; Hyunbeom Lee; Sang Youn Jung; C Justin Lee
Journal:  Exp Mol Med       Date:  2022-08-18       Impact factor: 12.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.